Crispr Therapeutics Ag (CRSP)
$63.56
1.70 (2.60%)
CRSP Stock Quote Delayed 30 Minutes
7 ‘FIRE’ Stocks to Put You on the Path to Financial Freedom
Because it’s tied to one of the six leading causes of “finality,” stress represents a silent public health crisis. And few things cause heightened stress…
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
5.02B
PE Ratio
-94.87
EPS
-0.67
Volume (Avg. Vol.)
1.08M
Day's Range
$63.49 - $65.39
52-Week Range
$37.55 - $91.10
Dividend & Yield
N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ag News
CRSP Stock Earnings: CRISPR Therapeutics Misses EPS, Misses Revenue for Q1 2024
CRSP stock results show that CRISPR Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition
Discover these three biotech stocks set for major gains with groundbreaking health solutions. Invest in the future of medicine.
3 Biopharma Stocks Predicted to Soar in Q2 2024
These biopharma stocks can produce massive returns for Q2 based on new product releases and international treatment approvals.
